Feingold syndrome type 2
FINE-gold SIN-drohm type 2
Also known as: Feingold type 2, MYCN-associated Feingold syndrome
At a Glance
What is Feingold syndrome type 2?
Feingold syndrome type 2 is a rare genetic disorder that primarily affects the development of the limbs and facial features. It is caused by mutations in the MYCN gene, which plays a crucial role in cell growth and development. Individuals with this condition often have small hands and feet, and may also have distinctive facial features such as a small jaw and narrow eyes. Over time, affected individuals may experience developmental delays and learning difficulties. Early symptoms can include feeding difficulties and growth delays, while later symptoms might involve speech and motor skill challenges. Early diagnosis is critical to manage symptoms and provide supportive therapies that can improve quality of life. The condition can impact family life by requiring ongoing medical care and support for developmental needs. Prognosis varies, but many individuals can lead fulfilling lives with appropriate interventions. Daily life may involve regular medical appointments, therapy sessions, and educational support. Families may need to adapt their routines to accommodate the needs of the affected individual. Social support and community resources can be beneficial in managing the condition. Awareness and understanding of the disorder can help in creating a supportive environment for those affected.
Medical Definition
Feingold syndrome type 2 is characterized by limb malformations, microcephaly, and facial dysmorphism due to mutations in the MYCN gene. Pathologically, it involves disrupted cellular proliferation and differentiation processes. Histological findings may include abnormalities in skeletal and neural tissues. It is classified under autosomal dominant genetic disorders with a rare occurrence. Epidemiologically, it affects a small number of individuals worldwide, with no specific prevalence data available. The disease course can vary, but typically involves congenital onset with lifelong management of symptoms.
Feingold syndrome type 2 Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Microcephaly manifests as a smaller than average head size for age and sex. It is caused by abnormal brain development during gestation or early infancy. Over time, it may lead to developmental delays and neurological issues. Daily life is affected by potential cognitive impairments, and supportive therapies can help manage developmental challenges.
Digital anomalies include brachydactyly and syndactyly, where fingers and toes are unusually short or fused. These occur due to disruptions in the normal development of limb buds during embryogenesis. As the child grows, these anomalies may lead to functional limitations in hand and foot use. Surgical intervention and occupational therapy can improve functionality and quality of life.
Facial dysmorphism presents with distinctive facial features such as a small jaw, wide-set eyes, and a high forehead. These features result from atypical craniofacial development. They remain relatively stable over time but may become more pronounced with age. While they do not typically impact health, they can affect social interactions, and counseling may be beneficial.
Common
Gastrointestinal atresias involve blockages or narrowing in parts of the digestive tract. These are due to incomplete development of the gastrointestinal organs. Symptoms can worsen without intervention, leading to feeding difficulties and malnutrition. Surgical correction is often necessary to restore normal digestive function and improve nutritional status.
Hearing loss in Feingold syndrome type 2 can range from mild to severe. It is often caused by structural abnormalities in the ear or auditory nerve. Without intervention, it can lead to speech and language delays. Hearing aids and speech therapy are crucial for enhancing communication skills and quality of life.
Developmental delay is characterized by slower achievement of motor, cognitive, and social milestones. It results from neurological impairments associated with the syndrome. The extent of delay varies, but early intervention can mitigate its impact. Tailored educational and therapeutic programs are essential for maximizing developmental potential.
Less Common
Keratoconus is a progressive thinning of the cornea, leading to a cone-shaped deformation. It is caused by structural changes in the corneal collagen fibers. Over time, it can result in significant visual impairment. Management includes corrective lenses or surgical options to improve vision.
Psychiatric disorders such as anxiety or depression may occur in some individuals. These are likely due to a combination of genetic factors and the psychosocial impact of living with a chronic condition. Symptoms can fluctuate, affecting daily functioning and quality of life. Psychological support and medication can help manage these conditions effectively.
What Causes Feingold syndrome type 2?
Feingold syndrome type 2 is primarily caused by mutations in the MYCN gene located on chromosome 2p24.3. The MYCN gene encodes a transcription factor that plays a crucial role in cell proliferation, differentiation, and apoptosis. Mutations in MYCN can lead to the production of an abnormal protein that fails to regulate gene expression effectively. This disruption in gene regulation affects the cell cycle and can lead to uncontrolled cell growth or impaired cell differentiation. As a result, there is dysfunction in pathways related to cell growth and development, particularly in neural and skeletal tissues. The abnormal cellular environment can trigger neuroinflammation, which further exacerbates tissue damage. This inflammation can lead to degeneration of white matter and other critical structures in the nervous system. The specific pattern of symptoms, such as microcephaly and digital anomalies, arises from the particular tissues and developmental stages affected by MYCN dysfunction. Variability in disease severity among patients is often due to differences in the specific mutations within the MYCN gene and the presence of modifier genes or environmental factors. Additionally, the immune response may vary between individuals, influencing the extent of neuroinflammation and tissue damage. Neighboring cells and tissues may experience altered signaling and support, leading to further dysfunction and symptom manifestation. The interplay between genetic, molecular, and environmental factors contributes to the heterogeneity of clinical presentations. Understanding the precise molecular mechanisms is crucial for developing targeted therapies. Research continues to explore how MYCN mutations specifically alter cellular pathways to refine treatment approaches. Insights into the role of MYCN in neural development may also shed light on potential therapeutic targets for related conditions.
How is Feingold syndrome type 2 Diagnosed?
Typical age of diagnosis: Feingold syndrome type 2 is typically diagnosed in early childhood, often when characteristic physical anomalies become apparent. Diagnosis may occur earlier if there is a known family history of the condition. Genetic counseling and testing are crucial for confirming the diagnosis. Early recognition allows for timely management of associated complications.
Clinicians look for characteristic features such as digital anomalies, microcephaly, and facial dysmorphism. A detailed family history is important to identify any hereditary patterns. Physical examination focuses on identifying limb malformations and craniofacial abnormalities. This step helps to narrow down the differential diagnosis and determine the need for further testing.
X-rays of the hands and feet are commonly used to identify digital anomalies. Specific abnormalities such as brachydactyly and clinodactyly can be visualized. Imaging findings support the clinical suspicion of Feingold syndrome type 2. They also help exclude other syndromes with overlapping features, such as skeletal dysplasias.
Routine laboratory tests may include complete blood count and metabolic panels to assess overall health. Biomarkers specific to Feingold syndrome type 2 are not typically available. Abnormal results may include electrolyte imbalances or renal function anomalies. These results guide further investigation and management, particularly if associated conditions are suspected.
Genetic testing focuses on sequencing the MYCN gene, known to be associated with Feingold syndrome type 2. Mutations such as deletions or point mutations in MYCN confirm the diagnosis. Genetic results provide definitive confirmation and are essential for family counseling. They also offer information on recurrence risk and guide prenatal testing options.
Feingold syndrome type 2 Treatment Options
Beta-blockers are used to manage cardiovascular symptoms associated with Feingold syndrome type 2. They work by blocking beta-adrenergic receptors, reducing heart rate and blood pressure. Commonly used drugs include propranolol and atenolol. Clinical evidence supports their efficacy in managing hypertension and arrhythmias in affected patients. Limitations include potential side effects such as fatigue and dizziness.
Occupational therapy focuses on improving fine motor skills and daily living activities. Techniques include exercises to enhance hand function and coordination. Sessions are typically conducted weekly and continue for several months. Measurable outcomes include improved dexterity and independence in daily tasks. Long-term benefits include enhanced quality of life and functional abilities.
Surgery is indicated for severe digital anomalies that impair function. The procedure involves reconstructing malformed digits to improve hand function. Expected benefits include enhanced grip and manual dexterity. Surgical risks include infection and limited range of motion post-operatively. Post-operative care includes physical therapy to maximize functional recovery.
The care team typically includes geneticists, cardiologists, orthopedic surgeons, and occupational therapists. Interventions focus on managing symptoms and preventing complications. Psychosocial support strategies include counseling and support groups for families. Family education is crucial for understanding the condition and managing daily challenges. Long-term monitoring involves regular follow-ups to assess growth, development, and emerging complications.
When to See a Doctor for Feingold syndrome type 2
- Severe difficulty breathing — this could indicate a serious respiratory complication requiring immediate medical attention.
- Sudden loss of consciousness — this may suggest a critical neurological event or severe metabolic imbalance.
- Acute chest pain — this could be a sign of a cardiovascular emergency and needs urgent evaluation.
- Persistent vomiting — this can lead to dehydration and electrolyte imbalances; consult a doctor if it continues.
- Unexplained weight loss — may indicate malabsorption or other underlying issues that require medical assessment.
- Frequent infections — suggest possible immune system involvement; a healthcare provider should evaluate this.
- Mild fatigue — monitor energy levels and ensure adequate rest and nutrition.
- Occasional headaches — track frequency and severity; maintain hydration and manage stress.
Feingold syndrome type 2 — Frequently Asked Questions
Is this condition hereditary?
Feingold syndrome type 2 is inherited in an autosomal dominant pattern, meaning one copy of the altered gene in each cell is sufficient to cause the disorder. There is a 50% chance of passing the condition to offspring if one parent is affected. De novo mutations can occur, meaning the mutation can appear for the first time in an individual with no family history. Carrier status is not applicable as the condition is not recessive. Genetic counseling is recommended for affected individuals and families to understand inheritance patterns and risks.
What is the life expectancy for someone with this condition?
Life expectancy can vary depending on the severity of symptoms and associated complications. Early diagnosis and management of symptoms can improve outcomes. Mortality is often related to complications such as respiratory or cardiac issues. Treatment and regular monitoring can enhance quality of life and potentially extend survival. Realistic expectations should include ongoing medical care and lifestyle adjustments.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, family history, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months due to the rarity of the condition. Specialists such as geneticists and pediatricians are usually involved in the diagnostic process. Delays in diagnosis may occur due to symptom overlap with other conditions. Genetic testing confirming mutations in specific genes associated with the syndrome finalizes the diagnosis.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and targeted molecular treatments as potential options. Novel approaches aim to address the underlying genetic causes of the syndrome. ClinicalTrials.gov is a resource for finding ongoing trials and new treatments. Patients should discuss with their doctors about eligibility for trials and potential benefits. New treatments may take several years to become widely available, depending on trial outcomes and regulatory approvals.
How does this condition affect daily life and activities?
Feingold syndrome type 2 can impact mobility and self-care, requiring physical therapy and adaptive aids. Educational support may be necessary due to learning difficulties or developmental delays. Social and emotional challenges can arise, necessitating psychological support and community resources. The condition can impose a significant family burden, with caregivers needing support and respite. Access to specialized services and adaptations can greatly enhance quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Feingold syndrome type 2 in a patient from China.
Lei J, Han L, Huang Y et al. · Am J Med Genet A · 2021 · PMID: 33818875
- 2.A fourth case of Feingold syndrome type 2: psychiatric presentation and management.
Ganjavi H, Siu VM, Speevak M et al. · BMJ Case Rep · 2014 · PMID: 25391829
- 3.First Patient Diagnosed as Feingold Syndrome Type 2 with Alport Syndrome and Review of the Current Literature.
Demir Ş, Söylemez MA, Arman A et al. · Mol Syndromol · 2022 · PMID: 36588757
- 4.A case of Feingold type 2 syndrome associated with keratoconus refines keratoconus type 7 locus on chromosome 13q.
Sirchia F, Di Gregorio E, Restagno G et al. · Eur J Med Genet · 2017 · PMID: 28159702
- 5.Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models.
Mirzamohammadi F, Kozlova A, Papaioannou G et al. · Nat Commun · 2018 · PMID: 29636449
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-03